Monoclonal antibodies and tyrosine-kinase inhibitors are two major targeted therapies for HER2-positive breast cancer but these cancer cells often quickly develop adaptive responses to these HER2-targeted therapies [28]. This evidence concerns the gene ERBB2 and breast carcinoma.